UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 859 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $13.08, for a total value of $11,235.72. Following the transaction, the insider now directly owns 145,091 shares of the company's stock, valued at approximately $1,897,790.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
UroGen Pharma Stock Down 5.5 %
Shares of UroGen Pharma stock opened at $13.05 on Friday. The business has a 50-day simple moving average of $15.21 and a 200-day simple moving average of $15.02. UroGen Pharma Ltd. has a one year low of $10.60 and a one year high of $20.70. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The company had revenue of $21.85 million during the quarter, compared to analysts' expectations of $23.69 million. On average, sell-side analysts forecast that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.
Institutional Inflows and Outflows
My grim warning about AI stocks
From Porter & Company | Ad
Today, I’m warning of another looming catastrophe.
Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out.
You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy...
There's also no escaping that The Big AI Die-Up is coming.
So go here now to read my new report The Big AI Die-Up… while you still can.
Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its stake in UroGen Pharma by 65.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company's stock valued at $89,000 after purchasing an additional 2,328 shares during the period. ProShare Advisors LLC purchased a new position in shares of UroGen Pharma during the second quarter worth about $199,000. Sierra Summit Advisors LLC acquired a new position in UroGen Pharma in the 4th quarter valued at about $218,000. BNP Paribas Financial Markets raised its stake in UroGen Pharma by 40.4% during the 4th quarter. BNP Paribas Financial Markets now owns 22,996 shares of the company's stock valued at $345,000 after acquiring an additional 6,617 shares during the last quarter. Finally, Main Street Financial Solutions LLC purchased a new stake in UroGen Pharma during the 2nd quarter valued at approximately $403,000. Hedge funds and other institutional investors own 91.29% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on URGN. Guggenheim began coverage on shares of UroGen Pharma in a research note on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price target on the stock. LADENBURG THALM/SH SH upped their price target on UroGen Pharma from $48.00 to $53.50 and gave the company a "buy" rating in a research note on Friday, June 14th. HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of UroGen Pharma in a report on Wednesday, August 14th. Finally, Oppenheimer lifted their target price on UroGen Pharma from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, June 14th.
Check Out Our Latest Report on URGN
About UroGen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
